Home › Compare › VAXX vs DVY

VAXX vs DVY: Dividend Comparison 2026

VAXX yields 1000000.00% · DVY yields 3.50%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VAXX wins by $4.7683925249533696e+36M in total portfolio value
10 years
VAXX
VAXX
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full VAXX calculator →
DVY
DVY
● Live price
3.50%
Share price
$150.03
Annual div
$5.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$437.78
Full DVY calculator →

Portfolio growth — VAXX vs DVY

📍 VAXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVAXXDVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VAXX + DVY cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VAXX pays
DVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VAXX
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
DVY
Annual income on $10K today (after 15% tax)
$297.17/yr
After 10yr DRIP, annual income (after tax)
$372.11/yr
At 15% tax rate, VAXX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VAXX + DVY for your $10,000?

VAXX: 50%DVY: 50%
100% DVY50/50100% VAXX
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VAXX buys
0
DVY buys
0
No recent congressional trades found for VAXX or DVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVAXXDVY
Forward yield1000000.00% ✓3.50%
Annual dividend / share$2.00$5.25 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.7683925249533696e+36M$25.1K ✓
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓$437.78
Total dividends collected$4.7683311610149396e+36M ✓$4.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VAXX vs DVY ($10,000, DRIP)

YearVAXX PortfolioVAXX Income/yrDVY PortfolioDVY Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,050$349.62+$100.00M → VAXX
2$934,786,450,701$934,679,439,252.34$12,184$361.04+$934786.44M → VAXX
3$8,165,787,108,578,292$8,164,786,887,076,042.00$13,409$372.07+$8165787108.56M → VAXX
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$14,730$382.68+$66665884190957.63M → VAXX
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$16,154$392.89+$508662171058048128.00M → VAXX
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$17,688$402.69+$3.62723524842849e+21M → VAXX
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$19,338$412.07+$2.417368115915061e+25M → VAXX
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$21,113$421.04+$1.5056740286145463e+29M → VAXX
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$23,020$429.61+$8.764771002818475e+32M → VAXX
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$25,070$437.78+$4.7683925249533696e+36M → VAXX

VAXX vs DVY: Complete Analysis 2026

VAXX — Stock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Full VAXX Calculator →

DVY — ETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →
📬

Get this VAXX vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VAXX vs SCHDVAXX vs JEPIVAXX vs OVAXX vs KOVAXX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.